This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Medpace Holdings's Median PS Value or its related term are showing as below:
MEDP's Price-to-Median-PS-Value is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.84 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Medpace Holdings Median PS Value Historical Data
The historical data trend for Medpace Holdings's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Medpace Holdings's Median PS Value
For the Diagnostics & Research subindustry, Medpace Holdings's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings's Price-to-Median-PS-Value Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
Medpace Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $61.722.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings (NAS:MEDP) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Medpace Holdings's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
389.77
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings Median PS Value Related Terms
Thank you for viewing the detailed overview of Medpace Holdings's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Medpace Holdings (Medpace Holdings) Business Description
Medpace is a late-stage contract research organization, or CRO, that provides full-service drug development and clinical trial services to small and midsized biotechnology, pharmaceutical, and medical device firms. Medpace also offers ancillary services such as bio-analytical laboratory services and imaging capabilities. The company was founded over 30 years ago, and it has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are principally based in the U.S., but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in February 2014, and it exited Medpace in August 2018.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MEDP has been successfully added to your 